Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | SHBG | P04278 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31540152 | 0.90 | MAPT (0.89) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL17951318 | 0.87 | SHBG (0.64) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL309536 | 0.86 | MAPT (0.78) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL29022975 | 0.86 | MAPT (0.78) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL20100924 | 0.85 | MAPT (1.00) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL28880629 | 0.85 | MAPT (1.00) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL23295187 | 0.85 | MAPT (0.65) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL29187749 | 0.85 | MAPT (0.65) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL17951346 | 0.84 | MAPT (0.79) | MAPTMAPK1KMT2ACYP19A1MEN1 | |
| SCHEMBL20100948 | 0.84 | MAPT (0.79) | MAPTMAPK1KMT2ACYP19A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | XIAMEN UNIVERSITY (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | XIAMEN UNIVERSITY (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | NR1H4, FABP1, NR1H2 | MAPT 4553/4885MAPK1 2029/4885KMT2A 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.